Human Papilloma Virus Infection Clinical Trial
Official title:
Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance.
clinical trial comparing the regression rate after 12 months of histologically confirmed cervical intraepithelial lesions 1 in 2 parallel groups. One group using the vaginal gel Papilocare® for 6 months and one group without any treatment.
Cervical cancer affects 3000 women and causes 1100 deaths every year in France. This type of cancer usually takes about 10 to 15 years to develop and has distinct precursor stages. Persistent infection by Human Papillomavirus is necessary for the development of these lesions. Currently, when a colposcopy biopsy reveals low grade lesion, it is recommanded to make a new cervical cytology or HPV testing, 12 months later. No treatment is recommended over this period. However 11% of these lesions evolve from low to high grade. Papilocare® is a vaginal gel that would improve the re-epithelialization of the uterine cervix. Creating a protective film on the cervix, it could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus. The goal of our study is to include 150 women with a histologically confirmed cervical intraepithelial lesions 1. Half of them will be using the vaginal gel Papilocare® for 6 month while the other half will not receive any treatment (as suggested by current recommendations). Each patient will have a cervical cytology and a HPV testing after 6 months and after 12 months. Therefore we will be able to compare the percentage of normalization of cervical cytology and HPV clearance for each group after 6 months and after 12 months. Patients will visit the Orleans hospital once for the inclusion and twice for follow-ups after 6 months and 12 months. If the use of Papilocare® really induces a significant regression of low grade lesions, this vaginal gel could be offered as soon as these lesions are histologically identified in order to stop its progress to high grade. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
| Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
| Active, not recruiting |
NCT02258659 -
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT02714114 -
Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)
|
N/A | |
| Completed |
NCT00303823 -
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
|
Phase 2 | |
| Not yet recruiting |
NCT05510830 -
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
|
N/A | |
| Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
| Not yet recruiting |
NCT06123533 -
Understanding Women's Values in Managing Human Papillomavirus (HPV)
|
||
| Completed |
NCT05694728 -
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
|
Phase 2 | |
| Completed |
NCT04391647 -
Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
|
||
| Recruiting |
NCT05439083 -
Immunogenicity of 9-valent HPV Vaccine
|
Phase 4 | |
| Completed |
NCT01446198 -
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System
|
N/A | |
| Completed |
NCT01539668 -
Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas
|
Phase 0 | |
| Recruiting |
NCT06467942 -
Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection
|
N/A | |
| Completed |
NCT01567813 -
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
|
||
| Completed |
NCT02811367 -
The HPV Self-test as a Test of Cure in Madagascar
|
N/A | |
| Completed |
NCT02067507 -
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
|
N/A | |
| Recruiting |
NCT01387997 -
e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses
|
N/A | |
| Completed |
NCT02634190 -
Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens
|
||
| Completed |
NCT00054041 -
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
|
Phase 2 |